Literature DB >> 15328165

Use of replicating oncolytic adenoviruses in combination therapy for cancer.

Roland L Chu1, Dawn E Post, Fadlo R Khuri, Erwin G Van Meir.   

Abstract

Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle. Viral-mediated tumor destruction is propagated through infection of nearby tumor cells by the newly released progeny. Each cycle should amplify the number of oncolytic viruses available for infection. Our understanding of the life cycles of cytolytic viruses has allowed manipulation of their genome to selectively kill tumor cells over normal tissue. Because the mechanism of tumor destruction is different, oncolytic virotherapy should work synergistically with current modes of treatment such as chemotherapy and radiation therapy. This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15328165     DOI: 10.1158/1078-0432.CCR-0349-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.

Authors:  Wei Zhu; Hongwei Zhang; Yi Shi; Mangen Song; Bijun Zhu; Lai Wei
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

2.  Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.

Authors:  J L Dembinski; E L Spaeth; J Fueyo; C Gomez-Manzano; M Studeny; M Andreeff; F C Marini
Journal:  Cancer Gene Ther       Date:  2009-10-30       Impact factor: 5.987

3.  Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

Authors:  Sonia Guedan; Juan José Rojas; Alena Gros; Elena Mercade; Manel Cascallo; Ramon Alemany
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

4.  A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters.

Authors:  Feng Liu; Kaya Xu; Hua Yang; Yuming Li; Jian Liu; Jixiang Wang; Zhizhong Guan
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

5.  Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.

Authors:  Karsten Geletneky; Andreas D Hartkopf; Robert Krempien; Jean Rommelaere; Joerg R Schlehofer
Journal:  J Biomed Biotechnol       Date:  2010-03-07

6.  A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Authors:  M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

7.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

8.  Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.

Authors:  Li Wang; Yunxin Zhang; Jinxia Zhao; Erlong Xiao; Jianzhong Lu; Shengjun Fu; Zhiping Wang
Journal:  Tumour Biol       Date:  2014-08-02

9.  Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Authors:  Guangyu Ma; Hideaki Shimada; Kenzo Hiroshima; Yuji Tada; Nobuo Suzuki; Masatoshi Tagawa
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors:  Miguel A Trujillo; Michael J Oneal; Julia Davydova; Elizabeth Bergert; Masato Yamamoto; John C Morris
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.